FP349
2505
Dr.Vidyadevi M
| Membership No | Author Name | Mobile | |
|---|---|---|---|
| 4702 | Dr.Swati | swatinagure02@gmail.com | 7899963998 |
Cataract
Loteprednol Etabonate 1% in Post-Phacoemulsification Care: A Ambispective Observational Study
Purpose: To evaluate the efficacy and safety of loteprednol etabonate 1% after uncomplicated phacoemulsification. Methods: 340 patients undergoing routine cataract surgery received loteprednol etabonate 1% for 4 weeks postoperatively. Outcomes assessed included anterior chamber inflammation (SUN grading), BCVA, IOP, corneal edema, wound healing, and adverse events. Results: Loteprednol 1% provided good control of postoperative inflammation and visual recovery. IOP remained stable in most patients, with minimal steroid response. Corneal edema and wound healing were satisfactory, with no major adverse events. Conclusion: Loteprednol etabonate 1% is an effective and safe postoperative steroid after phacoemulsification, with a favorable IOP profile and good clinical outcomes.
No Co-Author Selected